Independent
Tenure on this board
6.6 yrs
Also a director at
Mirum Pharmaceuticals Inc (MIRM)Mbx Biosciences Inc (MBX)
Meeting calendar
ARQT · Annual meeting · Friday, June 5, 2026
Arcutis Biotherapeutics Inc
3 nominees · 3 ballot items.
Three management proposals: (1) election of three Class III directors (Patrick J. Heron, Neha Krishnamohan, Todd Franklin Watanabe) for three-year terms; (2) ratification of Ernst & Young LLP as the independent registered public accounting firm for fiscal 2026; and (3) a non-binding advisory vote to approve the 2025 compensation of the Company’s named executive officers (say-on-pay).
Market cap
$3.5B
1Y TSR
+83.0%
Board grade
C
Record date
Apr 8, 2026
Filing
DEF 14A
Meeting concluded · Jun 5, 2026
Follow how the vote landed and what changed on Arcutis Biotherapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of Directors
ManagementBoard: FORElect three Class III directors—Patrick J. Heron, Neha Krishnamohan, and Todd Franklin Watanabe—to hold office until the 2029 annual meeting of stockholders.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the Audit Committee’s selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
- 3
Approval, on a Non-Binding Advisory Basis, of the Compensation of Our Named Executive Officers
ManagementBoard: FORNon-binding advisory (say-on-pay) vote to approve the fiscal year 2025 compensation of the Company’s named executive officers as disclosed in the proxy statement.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
3.9 yrs
Not independent
Tenure on this board
9.3 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | SUVRETTA CAPITAL MANAGEMENT, LLC | 9.9% | 12,327,000 | $290M |
| 2 | Frazier Life Sciences Management, L.P. | 7.9% | 9,874,511 | $233M |
| 3 | Rubric Capital Management LP | 6.6% | 8,271,577 | $195M |
| 4 | STATE STREET CORP | 5.0% | 6,296,197 | $148M |
| 5 | Polar Capital Holdings Plc | 4.5% | 5,666,940 | $134M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 4,871,536 | $115M |
| 7 | BlackRock, Inc. | 3.8% | 4,732,864 | $112M |
| 8 | GILDER GAGNON HOWE CO LLC | 3.4% | 4,304,010 | $101M |
| 9 | JENNISON ASSOCIATES LLC | 3.2% | 4,013,530 | $95M |
| 10 | MORGAN STANLEY | 3.1% | 3,823,421 | $90M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Arcutis Biotherapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Prestige Consumer Healthcare IncPBH
Annual meeting·Aug 4, 2026·$2.4B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.6B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.6B
Reference
Frequently asked questions
- When is the Arcutis Biotherapeutics Inc 2026 annual meeting?
- Arcutis Biotherapeutics Inc (ARQT) holds its 2026 annual shareholder meeting on Friday, June 5, 2026.
- What is the record date for the Arcutis Biotherapeutics Inc 2026 meeting?
- The record date for the Arcutis Biotherapeutics Inc 2026 meeting is Wednesday, April 8, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Arcutis Biotherapeutics Inc's 2026 meeting?
- The board is presenting 3 director nominees at the Arcutis Biotherapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Arcutis Biotherapeutics Inc 2026 meeting?
- Shareholders will vote on 3 proposals at the Arcutis Biotherapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.